KaydedilenlerDerginizi ekleyin

Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2005 / Cilt: 11 - Sayı: 3

A comparative study of effects of tibolone, conjugated equine estrogen alone or combination with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women

M. Ali YÜCE
Balkanlı Petek KAPLAN
Fatih GÜÇER
N. Cenk SAYIN
Mahmut YÜKSEL
Sayfa
189–193
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

CONCLUCION: Neither CEE alone nor combination of CEE with MPA or tibolone treatment causes significant changes in plasma homocysteine levels in postmenopausal women with normal baseline homocysteine levels.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: To assess the effect of estrogen, estrogen combined with progesterone or tibolon on serum total homocysteine levels, an independent risk factor for cardiovascular disorders, in postmenopausal women.
📊
Temel Bulgular & Veri:They received either conjugated equine estrogen 0.625 mg alone (CEE, n=16), CEE combined with medroxyprogesterone actate 5mg (CEE/MPA, n=20) or tibolon 2.5 mg (n=10).
💡
Sonuç & Katkı:CONCLUCION: Neither CEE alone nor combination of CEE with MPA or tibolone treatment causes significant changes in plasma homocysteine levels in postmenopausal women with normal baseline homocysteine levels.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Medroksiprogesteron · Kalp damar hastalıkları · Östrojenler

Abstract

OBJECTIVE: To assess the effect of estrogen, estrogen combined with progesterone or tibolon on serum total homocysteine levels, an independent risk factor for cardiovascular disorders, in postmenopausal women. STUDY DESIGN: In a randomised order, healthy, non-smoking postmenopausal women were included in the study. They received either conjugated equine estrogen 0.625 mg alone (CEE, n=16), CEE combined with medroxyprogesterone actate 5mg (CEE/MPA, n=20) or tibolon 2.5 mg (n=10). Treatments were given for three treatment cycles of 28 days (3 months). Plasma levels of homocysteine were measured at baseline and 3 months after the start of the study. RESULTS: There was no statistically significant change in plasma homocysteine levels in the only estrogen-treated group, sequentially combined CEE plus MPA-treated group and tibolone group. CONCLUCION: Neither CEE alone nor combination of CEE with MPA or tibolone treatment causes significant changes in plasma homocysteine levels in postmenopausal women with normal baseline homocysteine levels.

🔖

Bu Makaleye Atıf Yap

YÜCE, M. A., KAPLAN, B. P., GÜÇER, F., SAYIN, N. C., YÜKSEL, M. (2005). A comparative study of effects of tibolone, conjugated equine estrogen alone or combination with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 11 - Sayı: 3, 189–193. https://ajindex.com/articles/227307

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Boushey CJ, Beresford S A, Omenn GS, Motulsky AG. A quantitative assesment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-57
  2. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians JAMA 1992; 268:877-81
  3. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Eng J Med 1995; 332:286-91
  4. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med 1997; 337:230-6
  5. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk factor for coronary hearth disease determined by both and genetic and environmental influences. Q J Med 1993; 86:685-9
  6. Wouters MG, Moorrees MT, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25:801-5
  7. Morris MS, Jacques PF, Selhub J, Rosenberg IU. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2000; 152:140-8
  8. Anderson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after metionine loading with regard to age, gender and menopausal status. Eur J Clin Invest 1992; 22:79-87
  9. Cristodoulakos GE, Panoulis CPC, Rizos DA, Moustakarias T, Phocas I, Creatsas GC. Homocysteine and folate levels in postmenopausal women. Maturitas 2001; 39:161-7
  10. Moustapha A, Robinson K. Homocysteine: an emerging age-related cardiovascular risk factor. Geriatrics 1999; 54:49-63
  11. Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma after menopause. Atherosclerosis 2000; 149:163-8
  12. Anderson A, Hultberg BL, Brattstrom LE, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992; 30:377-9
  13. Brattstrom L, Israelsson B, Olsson A, Anderson A, Hultberg B. Plasma homocysteine in women on oral estrogen-containing contraceptives and in men with estrogen-teated prostatic carcinoma. Scand J Clin Lab Invest 1992; 52:283-7
  14. Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifene. Int J Cancer 1995; 60:365-8. 15.Mijatovic V, Kenemans P, Jakob